This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
InflaRx (IFRX) delivered earnings and revenue surprises of -23.81% and 83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
by Zacks Equity Research
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
by Zacks Equity Research
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
by Zacks Equity Research
Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.
InflaRx Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
Europe Equities Are Hot on Stimulus Optimism: 5 Picks
by Tirthankar Chakraborty
Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.
InflaRx Enters Oversold Territory
by Zacks Equity Research
InflaRx has been on a bit of a cold streak lately.
InflaRx Enters Oversold Territory
by Zacks Equity Research
InflaRx N.V. (IFRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.